Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA
Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CA
Philogen S.p.A. and its fully owned subsidiary Philochem AG, announce their participation to the “3rd ShanghaiTech-SIAIS BioForum”, 7-10 November 2016, Shanghai, China
Philogen S.p.A announces participation in the "3rd ShanghaiTech-SIAIS BioForum", 7-10 Shanghai, ChinaPhilogen S.p.A. announces participatio in the "World Immunotherapy Congress 2016", 14 - 16 November 2016, Basel, Switzerland
Philogen S.p.A. announces participation in the "World Immunotherapy Congress 2016", 14 - 16 November 2016, Basel, Switzerland
Philogen S.p.A announces participation in “PEGS Europe - Protein & Antibody Engineering Summit" , 31 October – 4 November 2016, Lisbon, Portugal
Philogen S.p.A announces participation in “PEGS Europe - Protein & Antibody Engineering Summit" , 31 October – 4 November 2016, Lisbon, PortugaPhilogen S.p.A. receives Orphan Drug Designation for the treatment of soft-tissue sarcoma
Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.
Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”, 28 August – 1 September 2016, Manchester, UK
Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”Philogen announced collaboration with Johnson & Johnson Innovation.
Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics.
Philogen SpA announced the successful GMP production of PHC-102 for the imaging of renal cell carcinoma and other carbonic anhydrase expressing tumors
Philogen SpA announced the successful GMP production of PHC-102
Philogen announce expanded research and development agreement with AbbVie
Philogen announces expanded research and development agreement with AbbVie
Philogen S.p.A. announced that Pfizer Inc. (NYSE: PFE) has exercised options granted under the agreement established in December 2014 for the potential development and commercialization of multiple antibody drug conjugates (ADCs). Siena, Italy, 21st January 2016.
Press Release Philogen Pfizer ADC option exercisePress release Melanoma Phase III
Philogen S.p.A announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. Siena, 21st January 2016.